2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
8
Lymphoid
6
Gastrointestinal
5
Thoracic
4
Dermatologic
4
Myeloid
3
Genitourinary
3
Endocrine
3
Breast
3
Plasma cell
2
Other solid neoplasm
2
Gynecologic
2
Sarcoma
1
NET
1
Head & Neck
1
Classical hematology
1
CNS
1
Conditions
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Interventions
lutetium Lu 177 dotatate
48
Everolimus
40
Magnetic Resonance Spectroscopy
21
lanreotide
17
Temozolomide
17
gallium Ga 68 dotatate
15
Octreotide
15
pembrolizumab
13
Nivolumab
13
surufatinib
12
Capecitabine
12
cabozantinib
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
11
Sunitinib
10
pasireotide
9
Specimen Handling
9
Positron Emission Tomography Computed Tomography
9
Lutetium-177
9
3-Iodobenzylguanidine
9
Ga(III)-DOTATOC
8
Carboplatin
8
telotristat ethyl
6
copper dotatate CU-64
6
amino-acid, glucose, and electrolyte solution
6
Somatostatin
6
Ipilimumab
6
Fluorodeoxyglucose F18
6
Etoposide
6
Cisplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biological Therapy
×
NET
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled